MAPK1 and neoplasm: Inhibitors that affect signaling downstream of KRAS4b such as the RAF inhibitor LY3009120 significantly inhibited tumor growth in murine models of skin and colon cancer, with a dose that inhibited 50% of Erk phosphorylation (ED50) of 4.36 mg/kg.